<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/ar309.anc" start="2073" end="2082" sStart="2064" offset="9" sid="r8.suggest.v.0880" wn="3" wnkey="suggest%2:32:02::" text="The data suggested clinical benefit as assessed from the mean change from baseline in the Crohn's Disease Severity Index after 21 days at doses of 16 and 40 ?g/kg per week ( P &lt; 0.05)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar309.anc" start="10265" end="10272" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="The sample size had a &gt;80% power to detect a 0.51 difference from the placebo &lt;b&gt;success&lt;/b&gt; &lt;b&gt;rate&lt;/b&gt; in at least one of the rhIL-11 treatment groups at the ? = 0.05 level of significance." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar309.anc" start="10265" end="10272" sStart="null" offset="0" sid="null" wn="1" wnkey="success%1:11:00::" text="The sample size had a &gt;80% power to detect a 0.51 difference from the placebo &lt;b&gt;success&lt;/b&gt; &lt;b&gt;rate&lt;/b&gt; in at least one of the rhIL-11 treatment groups at the ? = 0.05 level of significance." />
    <s path="[OANC]/data/written_2/technical/biomed/ar309.anc" start="6506" end="6512" sStart="null" offset="294" sid="r11.severe.j.0430" wn="1" wnkey="severe%5:00:00:intense:00" text="Screening clinical assessments included vital signs, counts of tender and swollen joints, the patient's global assessment and assessment of their pain, and a physician's global assessment using a 7-point Likert scale (0 = none, or good, to 7 = severe, or very bad)." />
    <s path="[OANC]/data/written_2/technical/biomed/ar309.anc" start="4084" end="4090" sStart="null" offset="458" sid="r11.severe.j.0429" wn="2147483644" wnkey="null" text="Exclusionary laboratory values included a platelet count of &gt; 500,000/mm 3, hematocrit &lt;30%, and a white-blood-cell count &lt; 3000/mm 3. Other exclusionary criteria included use of intravenous or intra-articular corticosteroids within four weeks of randomization, any prior use of cyclosporine or cyclophosphamide, use of any investigational agent within 30 days of randomization, severe extra-articular manifestations of RA, acute infection requiring antibiotic therapy within two weeks of randomization, other autoimmune disease (e.g." />
    <s path="[OANC]/data/written_2/technical/biomed/ar309.anc" start="1285" end="1291" sStart="null" offset="22" sid="r8.number.n.0657" wn="1" wnkey="number%1:07:00::" text="There are currently a number of anticytokine and other immune-modulating therapies in clinical trials [ 8]." />
  </sentences>
</list>